Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024312 (lymphopenia)
 4,859 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Bevacizumab is a monoclonal antibody, which neutralizes the effect of vascular endothelium growth factor (VEGF) allowing regression of tumour vessels and a decrease in the permeability of the blood-brain barrier. Already used in oncology as adjuvant treatment for certain metastatic cancers and in second line for high-grade gliomas, it has been recently used as a treatment of cerebral radionecrosis resisting conventional drug treatment and hyperbaric oxygen. This article presents three patients with cerebral radionecrosis and treated by monthly infusions of bevacizumab (10 mg/kg per month). The patients had developed cerebral radionecrosis after radiation therapy for a malignant brain tumour. The radionecrosis was proved by magnetic resonance imaging and spectroscopy. The first patient received only one perfusion of bevacizumab, as the development of a lymphopenia prevented the patient from continuing with the treatment. The second patient received four infusions, but the absence of improvement of the clinical symptoms and progression of the radiolesion led to discontinuation of the treatment. The third patient developed several severe side effects, a transient ischemic accident and a perforated corneal ulcer, resulting again in premature discontinuation of treatment. The development of severe side effects, combined with the absence of notable clinical and radiologic improvements resulting from the use of bevacizumab as a treatment resulted in the premature interruption of such treatment, in all three patients.
 ...
PMID:[Bevacizumab for the treatment of cerebral radionecrosis]. 2142 Jan 37

Bevacizumab is a well-established anti-VEGF monoclonal antibody that inhibits angiogenesis. Herein, we examined the response rates according to the grade of lymphopenia in metastatic breast cancer patients treated with bevacizumab+paclitaxel therapy. The objective responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline v1.1. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Twenty study patients were divided into group A (grade 2-4 lymphopenia) and group B (grade 1 lymphopenia or no decreased lymphocyte count) and compared. The mean progression-free survival (PFS)was 77.7 days in group A (n=7) and 56.8 days in group B (n=13). There was no significant difference between both groups (p=0.67, logrank test). The response rate (RR) was 14.3% (CR=0, PR=1, SD=3, PD=3) in group A, while in group B, it was 23.0% (CR=0, PR=3, SD= 6, PD=4). Furthermore, the clinical benefit rate (CBR) bwas 57.1% in group A and 69.2% in group B.
 ...
PMID:[Examination of the Response Rate of Paclitaxel and Bevacizumab Therapy for Metastatic Advanced Breast Cancer According to the Lymphopenia Grade]. 2648 62